The FDA is seeking 100 volunteers for its Secure Supply Chain Pilot Program that would allow them an easier path for product deliveries if they agree to certain standards.
Recalls are an unwanted expense for drugmakers, and if extensive enough, can be a drag on earnings. For Stericyle, which has a unit that helps companies manage recalls, they have been a moneymaker.
The company is investing substantially in plant expansions and manufacturing improvements over the next few years so it can produce more drugs more efficiently.
A developing situation in Texas, the death penalty leader in the U.S., illustrates how states are scrambling for supplies in the face of shortages of drugs used in lethal injections.
Alexion expects the new staff in Ireland will begin supplying its only marketed medicine, Soliris, by the end of this year, and the expanding workforce there will also manage supply of additional drugs to patients as they are approved.
Samsung BioLogics has said that its manufacturing prowess will enable it to make biologic drugs more cheaply than about anyone else. Bristol-Myers Squibb intends to find out via a 10-year pact for making a yet-to-be-approved cancer drug.
U.S.-based FMC will pay about $345 million to buy two premium-grade omega-3 plants from Trygg Pharma.
An updated supply agreement last fall between drugmakers and health officials in Ireland was expected to help keep drugs on shelves, but pharmacies in Ireland report shortages have only gotten worse in the last 12 months.
Intellectual Ventures is testing a device that can keep vaccines cool without power for 60 days, depending on outside temperature and humidity.
In April, the FDA said it had nailed one of the key players bringing counterfeit Avastin into the U.S. and wanted to make an example of him with federal jail time. But a judge in Montana has sentenced him to house arrest instead.